Serum sclerostin levels in renal cell carcinoma patients with bone metastases.
Sclerostin has been proposed as a potent inhibitor of bone formation. Sclerostin antibodies are under clinical development to treat osteoporosis and metastatic bone disease. Serum sclerostin level is elevated in multiple myeloma, an osteolytic malignancy, where it might serve as predictive marker for the use of sclerostin-directed antibodies. As renal cell carcinoma (RCC) patients often present with osteolytic metastases, we aimed to investigate serum sclerostin levels in RCC patients. Our study included 53 RCC patients (19 with bone metastases, 25 with visceral metastases and 9 with localized disease) and 53 age- and gender-matched non-osteoporotic controls. Frozen serum samples were subjected to sclerostin quantitative sandwich ELISA. The mean serum sclerostin levels of RCC patients and controls were 45.8 pmol/l and 45.1 pmol/l, respectively (p = 0.86). Analysis of variance showed no difference between the subgroups of RCC patients with regard to visceral or bone metastases or localized disease (p = 0.22). There was no significant association between eGFR (estimated glomerular filtration rate) and serum sclerostin levels in RCC patients (r = 0.05; p = 0.74) and controls (r = 0.06; p = 0.68). Our results indicate that serum sclerostin levels appear not to be a valuable biomarker to assess the occurrence of bone metastases in RCC patients.
Department of Orthopedic Surgery, Medical University of Graz, Graz, Austria.
C
C
Wibmer
Department of Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
K
K
Amrein
Department of Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
A
A
Fahrleitner-Pammer
Department of Orthopedic Surgery, Medical University of Graz, Graz, Austria.
M M
MM
Gilg
Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
A
A
Berghold
Department of Urology, Medical University of Graz, Graz, Austria.
G C
GC
Hutterer
Department of Orthopedic Surgery, Medical University of Graz, Graz, Austria.
W
W
Maurer-Ertl
Department of Medicine, Division of Oncology, Medical University of Graz, Graz, Austria.|Research Unit Genetic Epidemiology and Pharmacogenetics, Division of Clinical Oncology, Medical University of Graz, Graz, Austria.|CB-MED, Medical University of Graz, Graz, Austria.
A
A
Gerger
Department of Orthopedic Surgery, Medical University of Graz, Graz, Austria.
A
A
Leithner
Department of Medicine, Division of Oncology, Medical University of Graz, Graz, Austria.|Research Unit for non-coding RNAs and genome editing in cancer, Medical University of Graz, Graz, Austria.|Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
M
M
Pichler
Department of Medicine, Division of Oncology, Medical University of Graz, Graz, Austria.
J
J
Szkandera
J Am Geriatr Soc. 2014 Jun;62(6):1023-9
24779429
Osteoarthritis Cartilage. 2011 Jul;19(7):874-85
21619935
N Engl J Med. 2012 Jul 5;367(1):20-9
22762315
Calcif Tissue Int. 2013 Aug;93(2):121-32
23748710
PLoS One. 2015 Feb 06;10 (2):e0113482
25659076
Cancer Res. 2005 Sep 1;65(17):7554-60
16140917
Endocr Relat Cancer. 2009 Sep;16(3):703-13
19443538
Bone. 2011 Jan;48(1):160-6
20854942
J Biol Chem. 2008 Feb 29;283(9):5866-75
18089564
J Bone Joint Surg Am. 2014 Oct 1;96(19):1659-68
25274791
J Bone Miner Res. 2012 Nov;27(11):2259-63
22692843
Clin J Am Soc Nephrol. 2013 May;8(5):819-23
23430206
Blood Cancer J. 2011 Jun;1(6):e27
22829171
Curr Med Chem. 2011;18(20):3093-115
21651483
J Bone Miner Res. 2011 Feb;26(2):373-9
20721932
Int J Cancer. 2008 Sep 1;123(5):1034-42
18546262
Clin Endocrinol (Oxf). 2012 Jun;76(6):797-801
22151063
J Musculoskelet Neuronal Interact. 2010 Jun;10(2):128-35
20516629
Bone. 2012 Mar;50(3):739-42
22178539
Osteoporos Int. 2013 Feb;24(2):489-94
22525978
J Bone Miner Res. 2011 Jan;26(1):27-34
20499362
Breast Cancer Res Treat. 2011 Oct;129(3):737-46
21113658
Osteoporos Int. 2014 Feb;25(2):645-51
23903956
J Cell Physiol. 2014 Apr;229(4):453-62
24022654
Bone. 2004 Oct;35(4):828-35
15454089
Bone. 2013 Nov;57(1):272-6
23981659
J Bone Miner Res. 2012 Dec;27(12):2592-602
22836717
J Clin Endocrinol Metab. 2014 Jan;99(1):248-55
24187403
Int J Endocrinol. 2014;2014:715908
25053944
Kidney Blood Press Res. 2014;39(4):230-9
25118597
J Bone Miner Res. 2011 Jan;26(1):19-26
20593411
Cytokine Growth Factor Rev. 2005 Jun;16(3):319-27
15869900
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
25559415
J Clin Endocrinol Metab. 2012 Feb;97(2):311-25
22238383
Spine (Phila Pa 1976). 2011 Nov 1;36(23):1977-86
21304424
Expert Opin Emerg Drugs. 2011 Sep;16(3):441-58
21545247
J Clin Endocrinol Metab. 2012 Oct;97(10):3691-9
22865898
Calcif Tissue Int. 2011 Oct;89(4):327-34
21874545
Mod Pathol. 2008 Dec;21(12):1436-43
18931653
Int J Cancer. 2012 Sep 15;131(6):1466-71
22052418
J Bone Miner Res. 2015 Feb;30(2):216-24
25196993
J Clin Endocrinol Metab. 2012 Jan;97(1):148-54
21994959
N Engl J Med. 2014 Apr 24;370(17):1664-5
24758630
PLoS One. 2011;6(10 ):e25900
21991382
Mol Biol Cell. 2008 Feb;19(2):457-64
18032587
Eur Spine J. 2015 Oct;24(10):2133-41
25082760
J Bone Miner Res. 2009 Oct;24(10):1651-61
19419300
FASEB J. 2005 Nov;19(13):1842-4
16123173
Cancer Res. 2009 May 15;69(10):4097-100
19435905
J Bone Miner Res. 2011 Feb;26(2):229-38
21254230